A Phase 3 Clinical Study of KHK 4827

• Status: Completed
• Trial end date: 2016-07-04
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyowa Hakko Kirin Company, Limited; Kyowa Kirin Co., Ltd.
• Treatments: Brodalumab

Criteria

Inclusion Criteria:

• Subject has voluntarily signed the written informed consent form to participate in this study

• Subject has completed the week 52 evaluation either in Study 003 or 004

Exclusion Criteria:

• Subject has had a serious infection, defined as requiring systemic treatment with antibiotics or antivirals (excluding oral administration)

• Subject has been judged to be ineligible for participation in the study by the investigators/sub investigators